1. Home
  2. MGLD vs ELTX Comparison

MGLD vs ELTX Comparison

Compare MGLD & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Marygold Companies Inc.

MGLD

The Marygold Companies Inc.

N/A

Current Price

$0.96

Market Cap

44.8M

Sector

Finance

ML Signal

N/A

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$1.91

Market Cap

63.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGLD
ELTX
Founded
1996
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.8M
63.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
MGLD
ELTX
Price
$0.96
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
8.7K
339.6K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
$34,876,734.00
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$1.71
52 Week High
$1.38
$16.00

Technical Indicators

Market Signals
Indicator
MGLD
ELTX
Relative Strength Index (RSI) 43.04 24.48
Support Level $0.93 N/A
Resistance Level $1.07 $3.32
Average True Range (ATR) 0.05 0.14
MACD 0.00 -0.00
Stochastic Oscillator 36.83 18.23

Price Performance

Historical Comparison
MGLD
ELTX

About MGLD The Marygold Companies Inc.

The Marygold Companies Inc is an international holding company focused on acquiring and growing profitable businesses. Its main segments include U.S. Fund Management through USCF Investments, Food Products via Gourmet Foods and Printstock Products in New Zealand, Beauty Products under the Original Sprout brand, and formerly Security Systems through Brigadier, sold in 2025. The majority of revenue comes from fund management. The company operates in the USA, New Zealand, the United Kingdom, and Canada, with the majority of revenue generated from the USA. Its business approach focuses on strengthening financial services, expanding fintech, and managing a diverse portfolio for growth.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: